E-mail us:
service@prospectnews.com
Or call: 212 374 2800
Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
Add to balance / Manage account
Not logged in
Prospect News home
>
Main news index
>
All issuers starting with E
>
Issuers starting with E, PP only
>
All stories on Endocyte, Inc.
>
Stories on Endocyte, Inc., PP only
Search again
Enter part or all of the issuer name:
Market:
All markets
No structured products
Bank loans
Canadian bonds
CLOs
Convertibles
Distressed debt
Emerging markets
High yield
Investment grade
Liability management
Municipals
PIPEs
Preferreds
Private placements
All leveraged markets
Structured products
Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each.
All others are $1.00 each. Headlines in
gray
are not currently covered by your subscription.
Endocyte, Inc.
3/25/2014
PP
Endocyte cancels plans for $60 million at-the-market sales agreement
12/23/2013
PP
Endocyte announces plans for $60 million at-the-market sales agreement
8/2/2011
PP
Endocyte wraps $71.6 million public stock sale; greenshoe exercised
7/28/2011
PP
Endocyte prices $60.91 million public sale of stock at $1.80 per share
7/14/2011
PP
Endocyte to price public offering of stock to fund drug development
©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.
